Cargando…

Myeloma prognostic index at diagnosis might be a prognostic marker in patients newly diagnosed with multiple myeloma

BACKGROUND/AIMS: The aims of this study were to identify the value of inflammatory markers as pretreatment prognostic factors for patients with multiple myeloma (MM) and to estimate the value of a prognostic index including these markers at diagnosis. METHODS: A total of 273 newly diagnosed MM patie...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Dae Sik, Yu, Eun Sang, Kang, Ka-Won, Lee, Se Ryeon, Park, Yong, Sung, Hwa Jung, Choi, Chul Won, Kim, Byung Soo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Association of Internal Medicine 2017
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5511937/ https://www.ncbi.nlm.nih.gov/pubmed/27809455 http://dx.doi.org/10.3904/kjim.2016.054

Ejemplares similares

PVR (CD155) Expression as a Potential Prognostic Marker in Multiple Myeloma
por: Lee, Byung-Hyun, et al.
Publicado: (2022)

Prediction Model for Cereblon Expression in Bone Marrow Plasma Cells Based on Blood Markers in Multiple Myeloma Patients
por: Lee, Byung-Hyun, et al.
Publicado: (2021)

The effect of the response to the coronavirus disease pandemic on treatment outcomes in patients with lymphoma and multiple myeloma
por: Kang, Ka-Won, et al.
Publicado: (2021)

Modified dose of melphalan-prednisone in multiple myeloma patients receiving bortezomib plus melphalan-prednisone treatment
por: Lee, Se Ryeon, et al.
Publicado: (2019)

Prognostic value of the nutritional risk index in patients with newly diagnosed multiple myeloma
por: Zhang, Limei, et al.
Publicado: (2022)

Bortezomib and melphalan as a conditioning regimen for autologous stem cell transplantation in multiple myeloma
por: Lee, Se Ryeon, et al.
Publicado: (2010)

Prognostic Nomogram for the Overall Survival of Patients with Newly Diagnosed Multiple Myeloma
por: Zhang, Yue, et al.
Publicado: (2019)

Prognostic outcomes of cytomegalovirus reactivation after autologous stem cell transplantation
por: Lee, Byung-Hyun, et al.
Publicado: (2023)

Implications and prognostic impact of mass spectrometry in patients with newly-diagnosed multiple myeloma
por: Mai, Elias K., et al.
Publicado: (2023)

The prognostic significance of circulating plasma cells in newly diagnosed multiple myeloma patients
por: Yao, Weiqin, et al.
Publicado: (2023)

Prognostic Value of Galectin-9 Relates to Programmed Death-Ligand 1 in Patients With Multiple Myeloma
por: Lee, Byung-Hyun, et al.
Publicado: (2021)

Development and validation of prognostic implications of chromosome abnormalities algorithm for newly diagnosed multiple myeloma
por: Luo, Tiancheng, et al.
Publicado: (2020)

A prognostic index for multiple myeloma.
por: Grignani, G., et al.
Publicado: (1996)

Peripheral Absolute Lymphocyte Count: An Economical and Clinical Available Immune-Related Prognostic Marker for Newly Diagnosed Multiple Myeloma
por: Yang, Ying, et al.
Publicado: (2020)

Prognostic Value of Association of Copy Number Alterations and Cell-Surface Expression Markers in Newly Diagnosed Multiple Myeloma Patients
por: Dragoș, Mihaiela L., et al.
Publicado: (2022)

Comparison between 5-day decitabine and 7-day azacitidine for lower-risk myelodysplastic syndromes with poor prognostic features: a retrospective multicentre cohort study
por: Lee, Byung-Hyun, et al.
Publicado: (2020)

Severe renal impairment as an adverse prognostic factor for survival in newly diagnosed multiple myeloma patients
por: Chen, Xuduan, et al.
Publicado: (2020)

The prognostic value of the MASS in a multi-center cohort of patients with newly diagnosed multiple myeloma
por: Yang, Peiyu, et al.
Publicado: (2022)

Bone-Related Extramedullary Disease in Newly Diagnosed Myeloma Patients is an Independent Poor Prognostic Predictor
por: Wang, Ying, et al.
Publicado: (2022)

Echocardiography‐defined pulmonary hypertension is an adverse prognostic factor for newly diagnosed multiple myeloma patients
por: Jian, Yuan, et al.
Publicado: (2022)

P22 THE PROGNOSTIC ROLE OF 1Q ABNORMALITIES IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS
por: Attucci, I., et al.
Publicado: (2023)

Comparison of the Freiburg and Charlson Comorbidity Indices in Predicting Overall Survival in Elderly Patients with Newly Diagnosed Multiple Myeloma
por: Kim, Sung Min, et al.
Publicado: (2014)

Higher proportion of non-classical and intermediate monocytes in newly diagnosed multiple myeloma patients in Egypt: A possible prognostic marker
por: Zahran, Asmaa M., et al.
Publicado: (2021)

Distinct Clinical Outcomes between Paramedullary and Extramedullary Lesions in Newly Diagnosed Multiple Myeloma
por: Batsukh, Khishigjargal, et al.
Publicado: (2017)

Prognostic value of integrated cytogenetic, somatic variation, and copy number variation analyses in Korean patients with newly diagnosed multiple myeloma
por: Lee, Nuri, et al.
Publicado: (2021)

Peripheral Blood Lymphocyte-to-Monocyte Ratio as a Useful Prognostic Factor in Newly Diagnosed Multiple Myeloma
por: Tian, Ying, et al.
Publicado: (2018)

Significance of the absolute lymphocyte/monocyte ratio as a prognostic immune biomarker in newly diagnosed multiple myeloma
por: Dosani, T, et al.
Publicado: (2017)

The Prognostic Role of Prothrombin Time and Activated Partial Thromboplastin Time in Patients with Newly Diagnosed Multiple Myeloma
por: Geng, Chuanying, et al.
Publicado: (2021)

Baseline peripheral neuropathy was associated with age and a prognostic factor in newly diagnosed multiple myeloma patients
por: Dong, Mengmeng, et al.
Publicado: (2022)

Frontline therapy for newly diagnosed patients with multiple myeloma
por: Jung, Sung-Hoon, et al.
Publicado: (2020)

Extreme body mass index and survival in newly diagnosed multiple myeloma patients
por: Shah, Urvi A., et al.
Publicado: (2023)

Body Mass Index and Overall Survival of Patients with Newly Diagnosed Multiple Myeloma
por: Wang, Bei, et al.
Publicado: (2022)

Corrigendum: Higher proportion of non-classical and intermediate monocytes in newly diagnosed multiple myeloma patients in Egypt: A possible prognostic marker
por: Zahran, Asmaa M., et al.
Publicado: (2022)

Oprozomib in patients with newly diagnosed multiple myeloma
por: Hari, Parameswaran, et al.
Publicado: (2019)

Daratumumab in untreated newly diagnosed multiple myeloma
por: Abdallah, Nadine, et al.
Publicado: (2019)

Acquired platelet dysfunction in newly diagnosed myeloma
por: Mortimer, Joshua, et al.
Publicado: (2021)

A Focus on Newly Diagnosed Multiple Myeloma
por: Brigle, Kevin, et al.
Publicado: (2022)

Prognostic implications of abnormalities of chromosome 13 and the presence of multiple cytogenetic high-risk abnormalities in newly diagnosed multiple myeloma
por: Binder, M, et al.
Publicado: (2017)

Diagnosing myeloma in general practice: how might earlier diagnosis be achieved?
por: Smith, Lesley, et al.
Publicado: (2022)

Clinical significance of granule‐containing myeloma cells in patients with newly diagnosed multiple myeloma
por: Suzuki, Kazuhito, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_bon9pmve6sbrbsh17ltvk9sk28